Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 6;16(8):e66258.
doi: 10.7759/cureus.66258. eCollection 2024 Aug.

A Systematic Review of the Cardiotoxic Effects of Targeted Therapies in Oncology

Wilhelmina N Hauwanga  1 , Billy McBenedict  2 , Emmanuel S Amadi  3 , Taha K Dohadwala  4 , Chukwuwike Johnny  5 , Felix Asaju  2 , Onyinye D Okafor  6 , Abdulmalik Jimoh  7 , Ada Andrea Oghenerukevwe Elumah  2 , Okam V Onyinyinyechi  8 , Dulci Petrus  9 , Bruno Lima Pessôa  2
Affiliations
Review

A Systematic Review of the Cardiotoxic Effects of Targeted Therapies in Oncology

Wilhelmina N Hauwanga et al. Cureus. .

Abstract

Cancer therapy advancements have improved survival rates but also introduced significant cardiotoxic risks. Cardiotoxicity, a critical adverse effect of cancer treatments such as doxorubicin, trastuzumab, and radiotherapy, poses substantial challenges. This systematic review synthesizes findings from studies on cardiotoxicity induced by cancer therapies, focusing on detection and management. Key predictors of chemotherapy-induced myocardial toxicity (CIMT) include advanced age, hypertension, hyperlipidemia, diabetes, and elevated N-terminal pro-B-type natriuretic peptide levels. Regular echocardiographic assessments, particularly of the left ventricular global longitudinal strain (LVGLS) and left ventricular ejection fraction (LVEF), are essential for early detection. The CardTox-Score, incorporating these risk factors, shows high sensitivity and specificity in predicting CIMT. Advanced imaging techniques and biomarkers play crucial roles in identifying at-risk patients before functional decline. Early biomarkers and imaging techniques such as LVGLS and LVEF are effective in diagnosing and managing cardiotoxicity, allowing timely interventions. Cardiology involvement in patient care significantly enhances adherence to cardiac monitoring guidelines and reduces cardiotoxicity risks. Management strategies emphasize regular cardiac monitoring, patient education, and the use of cardioprotective agents. A collaborative approach between cardiologists and oncologists is vital to assess cardiovascular risks, minimize vascular toxicity, and manage long-term adverse effects, ensuring the safety and efficacy of cancer therapies. This review underscores the importance of early detection and proactive management of cardiotoxicity in cancer patients to optimize treatment outcomes and improve quality of life.

Keywords: cancer; cardioprotective; cardiotoxicity; chemotherapy; ejection fraction.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram indicating the steps taken to filter the articles for this review
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Mapping cancer origins. Gilbertson RJ. Cell. 2011;145:25–29. - PMC - PubMed
    1. Cardiotoxicity of doxorubicin treatment and physical activity: a systematic review. Maia TN, de Araujo GBR, Teixeira JAC, Junior EDA, Dias KP. Int J Cardiovasc Sci. 2017;30:70–80.
    1. Cancer statistics, 2024. Siegel RL, Giaquinto AN, Jemal A. CA Cancer J Clin. 2024;74:12–49. - PubMed
    1. Cancer therapy-induced cardiotoxicity—a metabolic perspective on pathogenesis, diagnosis and therapy. Choksey A, Timm KN. Int J Mol Sci. 2021;23:441. - PMC - PubMed
    1. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature. Wojtacki J, Lewicka-Nowak E, Leśniewski-Kmak K. https://medscimonit.com/abstract/index/idArt/508559 Med Sci Monit. 2020;6:411–420. - PubMed

LinkOut - more resources